The combined targeting of EGFR and NOTCH signaling in CD133+ cells proposed by Shang et al. offers a compelling strategy to overcome the limited efficacy of EGFR inhibitors in endometrial cancer. The gene discussed is PROM1; the disease is endometrial cancer.